Symptomatic hyperammonemia secondary to recombinant Erwinia asparaginase

Pediatr Blood Cancer. 2023 May;70(5):e30208. doi: 10.1002/pbc.30208. Epub 2023 Jan 12.

Authors

Catherine E Martin¹, Mira A Kohorst², Asmaa Ferdjallah², Jessica L Kalmes², Heather M Johnson², Paul J Galardy², Shakila P Khan², Alexis K Kuhn¹

Affiliations

¹ Department of Pharmacy - Ambulatory Service, Mayo Clinic, Rochester, Minnesota, USA.
² Department of Pediatric and Adolescent Medicine, Division of Pediatric Hematology/Oncology, Mayo Clinic, Rochester, Minnesota, USA.

PMID: 36633209
DOI: 10.1002/pbc.30208

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents* / therapeutic use
Asparaginase / adverse effects
Erwinia*
Humans
Hyperammonemia* / chemically induced
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / complications
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy

Substances

Asparaginase
Antineoplastic Agents